These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33722066)

  • 1. Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis.
    Claassens DMF; Bergmeijer TO; Vos GJA; Hermanides RS; van 't Hof AWJ; van der Harst P; Barbato E; Morisco C; Tjon Joe Gin RM; Asselbergs FW; Mosterd A; Herrman JR; Dewilde WJM; Janssen PWA; Kelder JC; Mahmoodi BK; Deneer VHM; Ten Berg JM
    Circ Cardiovasc Interv; 2021 Apr; 14(4):e009434. PubMed ID: 33722066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcomes and Sustainability of Using
    Lee CR; Sriramoju VB; Cervantes A; Howell LA; Varunok N; Madan S; Hamrick K; Polasek MJ; Lee JA; Clarke M; Cicci JD; Weck KE; Stouffer GA
    Circ Genom Precis Med; 2018 Apr; 11(4):e002069. PubMed ID: 29615454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
    JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case for genotype-guided de-escalation of antiplatelet therapy after percutaneous coronary angioplasty.
    Cavallari LH; Lee CR
    Future Cardiol; 2019 Jul; 15(4):251-254. PubMed ID: 31385522
    [No Abstract]   [Full Text] [Related]  

  • 5. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
    Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND
    Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of P2Y
    Thomas CD; Williams AK; Lee CR; Cavallari LH
    Pharmacotherapy; 2023 Feb; 43(2):158-175. PubMed ID: 36588476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention.
    Coughlan JJ; Aytekin A; Ndrepepa G; Schüpke S; Bernlochner I; Mayer K; Neumann FJ; Menichelli M; Richardt G; Wöhrle J; Witzenbichler B; Gewalt S; Xhepa E; Kufner S; Sager HB; Joner M; Ibrahim T; Fusaro M; Laugwitz KL; Schunkert H; Kastrati A; Cassese S
    Circ Cardiovasc Interv; 2021 Jul; 14(7):e010565. PubMed ID: 34130477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
    AlMukdad S; Elewa H; Al-Badriyeh D
    J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Clinical Implementation of
    Azzahhafi J; Broek WWAVD; Chan Pin Yin DRPP; Harmsze AM; van Schaik RHN; Ten Berg JM
    J Cardiovasc Pharmacol Ther; 2023; 28():10742484231210704. PubMed ID: 37899583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison Between Clopidogrel and Prasugrel Associated With CYP2C19 Genotypes in Patients Receiving Percutaneous Coronary Intervention in a Japanese Population.
    Sawayama Y; Yamamoto T; Tomita Y; Asada K; Yagi N; Fukuyama M; Miyamoto A; Sakai H; Ozawa T; Isono T; Hira D; Terada T; Horie M; Nakagawa Y
    Circ J; 2020 Aug; 84(9):1575-1581. PubMed ID: 32713878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: A randomized comparative study.
    Kitano D; Takayama T; Fukamachi D; Migita S; Morikawa T; Tamaki T; Kojima K; Mineki T; Murata N; Akutsu N; Sudo M; Hiro T; Hirayama A; Okumura Y
    Catheter Cardiovasc Interv; 2020 Jan; 95(1):E8-E16. PubMed ID: 30983087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.
    Mohareb MW; AbdElghany M; Zaki HF; El-Abhar HS
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):478-488. PubMed ID: 32675750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
    Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
    JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
    Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
    Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet Therapy and Bleeding Outcomes With CYP2C19 Genotyping.
    Coons JC; Stevenson JM; Patel A; Smith AJC; Prebehalla L; Empey PE
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221143246. PubMed ID: 36503270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis.
    Yoon HY; Lee N; Seong JM; Gwak HS
    Br J Clin Pharmacol; 2020 Aug; 86(8):1489-1498. PubMed ID: 32320492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
    Máchal J; Hlinomaz O
    Curr Vasc Pharmacol; 2019; 17(1):35-40. PubMed ID: 29412111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
    Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J
    Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Genotype-Guided Strategy for Oral P2Y
    Claassens DMF; Vos GJA; Bergmeijer TO; Hermanides RS; van 't Hof AWJ; van der Harst P; Barbato E; Morisco C; Tjon Joe Gin RM; Asselbergs FW; Mosterd A; Herrman JR; Dewilde WJM; Janssen PWA; Kelder JC; Postma MJ; de Boer A; Boersma C; Deneer VHM; Ten Berg JM
    N Engl J Med; 2019 Oct; 381(17):1621-1631. PubMed ID: 31479209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI: Results of the GIANT Study.
    Hulot JS; Chevalier B; Belle L; Cayla G; Khalife K; Funck F; Berthier R; Piot C; Tafflet M; Montalescot G;
    JACC Cardiovasc Interv; 2020 Mar; 13(5):621-630. PubMed ID: 32139220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.